A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
|Videos|March 11, 2011
Dr. Pearlstone on Breast Cancer's 10 Year Progression
Author(s)David Pearlstone, MD
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years
Advertisement
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years
Advertisement
Related to this article
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5